Capsaicin-loaded vesicular systems designed for enhancing localized delivery for psoriasis therapy
Source abstract
Abstract
The aim of the current investigation is to evaluate the potential of capsaicin (CAP)-containing liposomes, niosomes and emulsomes in providing localized and controlled delivery, to improve the topical delivery of drug. CAP-bearing systems were prepared by the film hydration method and compared through various in vitro and in vivo parameters. The TEM photographs suggested that the carrier systems were spherical in shape and nanometric in size range. Skin retention studies of CAP from in vitro and in vivo experiments revealed significantly higher accumulation of drug in the case of the emul-gel formulation. Based on the results, we concluded that the emul-gel may be a potential approach for the topical delivery of CAP, for an effective therapy for psoriasis.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Dermatology and Skin Diseases · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (34)
Show source-provided references
1. 10.1016/S0378-5173(01)00810-910.1016/S0378-5173(01)00810-9 ↗
2. 10.3109/21691401.2013.83268310.3109/21691401.2013.832683 ↗
3. 10.1016/j.ijpharm.2010.09.00710.1016/j.ijpharm.2010.09.007 ↗
4. 10.1016/S0163-7827(02)00028-010.1016/S0163-7827(02)00028-0 ↗
5. Carter RB · Drug Dev Res · 1991 · 22 · 10910.1002/ddr.430220202 ↗
6. Carter RB · Neurosci Lett · 1991 · 127 · 4910.1016/0304-3940(91)90890-6 ↗
7. Chhabra N · J Nutri Pharmacol Neurolog Dis · 2012 · 2 · 810.4103/2231-0738.93124 ↗
8. 10.1016/j.jconrel.2007.08.00510.1016/j.jconrel.2007.08.005 ↗
9. 10.1016/j.ejps.2008.05.00210.1016/j.ejps.2008.05.002 ↗
10. 10.1016/0003-2697(78)90172-010.1016/0003-2697(78)90172-0 ↗
11. 10.3109/0898210100359612510.3109/08982101003596125 ↗
12. Gupta M · Pharma Dev Technol · 2013 · 18 · 55010.3109/10837450.2011.598161 ↗
13. 10.1016/j.ijpharm.2004.12.02210.1016/j.ijpharm.2004.12.022 ↗
14. 10.1080/1061186070145383610.1080/10611860701453836 ↗
15. Harada N · Growth Hormone IGF Res · 2007 · 17 · 17110.1016/j.ghir.2006.12.005 ↗
16. Kenins P · Neurosci Lett · 1982 · 29 · 8310.1016/0304-3940(82)90369-X ↗
17. 10.1016/j.ejpb.2012.04.00510.1016/j.ejpb.2012.04.005 ↗
18. Lademann J · Skin Pharmacol Physiol · 2008 · 21 · 15010.1159/000131079 ↗
19. Lawrence MJ · STP Pharm Sci · 1996 · 6 · 49
20. 10.1016/S0378-5173(99)00337-310.1016/S0378-5173(99)00337-3 ↗
21. 10.1016/S0927-7765(03)00080-810.1016/S0927-7765(03)00080-8 ↗
22. Mukherjee B · Int J Nanomed · 2007 · 2 · 213
23. 10.1016/S0378-5173(01)00637-810.1016/S0378-5173(01)00637-8 ↗
24. 10.1016/j.ijpharm.2009.01.01410.1016/j.ijpharm.2009.01.014 ↗
25. 10.1016/j.jconrel.2008.04.01910.1016/j.jconrel.2008.04.019 ↗
26. 10.3109/02652048.2012.71711510.3109/02652048.2012.717115 ↗
27. 10.3109/02652048.2010.54643510.3109/02652048.2010.546435 ↗
28. 10.1016/0169-409X(95)00019-410.1016/0169-409X(95)00019-4 ↗
29. 10.1016/j.ijpharm.2007.05.06110.1016/j.ijpharm.2007.05.061 ↗
30. 10.1016/j.ijpharm.2004.02.03210.1016/j.ijpharm.2004.02.032 ↗
31. Tavano L · Colloids Sur B Biointerfaces · 2011 · 87 · 33310.1016/j.colsurfb.2011.05.041 ↗
32. 10.1016/S0168-3659(99)00222-910.1016/S0168-3659(99)00222-9 ↗
33. Traub M · Alternative Med Rev · 2007 · 12 · 319
34. Turini MPD · Urology · 2006 · 67 · 91010.1016/j.urology.2005.11.028 ↗